BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-605@pharmaconomics
DTSTAMP:20260707T021326Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:PVLA Phase 2 — QTORIN™ pitavastatin (estimated date)
DESCRIPTION:Phase 2 trial results for QTORIN™ pitavastatin in disseminated superficial actinic porokeratosis are due ~ Dec 31\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1583648/000119312526210605/pvla-ex99_1.htm\n\nTrack it: https://pharmaconomics.com/e/605
URL:https://pharmaconomics.com/e/605
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:PVLA catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR